Advertisements



Shire sells cancer drugs to Servier for $2.4B as Takeda circles

Shire said on Monday it would consider returning proceeds from the sale to shareholders through a buyback and that further selective disposals of non-strategic assets were possible......»»

Category: topSource: foxnewsApr 16th, 2018

Shire sells cancer drugs to Servier as Takeda circles

Shire, the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceu.....»»

Category: videoSource: reutersApr 16th, 2018

Shire sells cancer drugs to Servier for $2.4B as Takeda circles

Shire said on Monday it would consider returning proceeds from the sale to shareholders through a buyback and that further selective disposals of non-strategic assets were possible......»»

Category: topSource: foxnewsApr 16th, 2018

Shire sells cancer drugs to Servier for $2.4 billion as Takeda circles

LONDON (Reuters) - Shire , the London-listed rare diseases specialist that is a potential takeover target for Japan's Takeda Pharmaceutical , is selling its oncology business to unlisted French drugmaker Servier for $2.4 billion......»»

Category: topSource: reutersApr 16th, 2018

Shire Sells Oncology Unit Ahead of Takeda"s Potential Offer

Shire (SHPG) sells its oncology segment to France-based Servier for $2.4 billion. T.....»»

Category: smallbizSource: nytApr 17th, 2018

The Wall Street Journal: In turnaround, Pfizer pins growth on cancer drugs

Twenty years ago, Pfizer Inc. didn’t sell any drugs treating cancer. Now, it sells 17, including four that were approved in the U.S. at the end of last year, more than any other pharmaceutical company......»»

Category: topSource: marketwatchJan 27th, 2019

Takeda clears key hurdle as investors back $59 billion Shire deal

Takeda Pharmaceutical has won shareholder approval for its $59 billion takeover of London-listed Shire , creating a global powerhouse that has a stronger drugs pipeline but is also saddled with massive debt......»»

Category: topSource: reutersDec 5th, 2018

$59bln: What it costs to become a drugs player

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt. Julian Satterthwaite reports......»»

Category: videoSource: reutersDec 5th, 2018

Takeda investors back $59 billion Shire deal, but wary of debt load

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt......»»

Category: topSource: reutersDec 5th, 2018

Takeda shareholders give nod for $59 billion Shire acquisition

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt......»»

Category: topSource: reutersDec 4th, 2018

Takeda shareholders approve Shire acquisition: spokesman

Takeda Pharmaceutical shareholders approved on Wednesday its $59 billion takeover of London-listed Shire , a Takeda spokesman said, creating a global powerhouse with a stronger drugs pipeline but one that is saddled with massive debt......»»

Category: topSource: reutersDec 4th, 2018

Japan"s Takeda clinches $62 billion Shire deal as pharma M&A rolls on

LONDON/TOKYO (Reuters) - Takeda Pharmaceutical agreed to buy London-listed Shire for 45.3 billion pounds ($62 billion) on Tuesday, the biggest yet in a wave of deals sweeping the drugs industry......»»

Category: topSource: reutersMay 8th, 2018

Japan"s Takeda sweetens $62 billion Shire offer

TOKYO/LONDON (Reuters) - Japan's Takeda Pharmaceutical nudged up its offer for Shire to 44.3 billion pounds ($62 billion) on Friday to try to persuade the rare-disease drugs specialist into talks after it rejected three previous proposals......»»

Category: topSource: reutersApr 20th, 2018

Shire to Sell Oncology Unit as Takeda Mulls Takeover

Shire has agreed to sell its oncology business to French drugmaker Servier for $2.4 billion, in a deal that could discourage Takeda from launching a takeover......»»

Category: smallbizSource: wsjApr 16th, 2018

Shire to Sell Oncology Unit for $2.4 Billion as Takeda Mulls Takeover

Shire has agreed to sell its oncology business to French drugmaker Servier for $2.4 billion, in a deal that could discourage Takeda from launching a takeover......»»

Category: smallbizSource: wsjApr 16th, 2018

J&J beats estimates on pharma strength, raises sales forecast

Johnson & Johnson beat quarterly profit estimates on Tuesday and raised its adjusted sales growth forecast for the year, driven by demand for its treatment for psoriasis and Crohn's disease and cancer drugs Darzalex and Imbruvica......»»

Category: topSource: reutersApr 16th, 2019

Merrimack Discontinues Cancer Study Amidst Layoffs

Merrimack Pharmaceuticals shares dipped on Friday after the firm announced that it would be discontinuing one of its cancer drugs as well as conducting layoffs......»»

Category: blogSource: 247wallstApr 5th, 2019

Iowa State Bank Buys The Walt Disney Co, Schlumberger, CVS Health Corp, Sells Shire PLC, ...

Related Stocks: SLB, CVS, NOV, DE, DIS, MDLZ, WRE, SHPG,.....»»

Category: worldSource: nytApr 4th, 2019

Brainstorm Health: AI and Old Drugs, Gene Editing Registry, AbbVie Cancer Drug

Brainstorm Health Daily.....»»

Category: europeSource: fortuneMar 19th, 2019

Glenview Capital Management Buys Cigna Corp, Shire PLC, DXC Technology Co, Sells Express ...

Related Stocks: CI, SHPG, DXC, GOOGL, CVS, BHC, BAX, HUM, LTHM, AGN, FDX, TMO,.....»»

Category: blogSource: gurufocusMar 14th, 2019

126 lots of popular blood pressure medication recalled for cancer risk

Three companies recalled 126 lots of the blood pressure drugs losartan and valsartan this week after discovering small amounts of probable carcinog.....»»

Category: topSource: usatodayMar 1st, 2019